Larson Financial Group
ALNY icon

Larson Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Larson Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$460K Buy
1,866
+1,253
+204% +$319K 0.01% 626
2026
Q2 		$185K Buy
613
+288
+89% +$86.9K ﹤0.01% 883
2026
Q1 		$108K Buy
325
+84
+35% +$28.6K ﹤0.01% 959
2025
Q4 		$95.8K Sell
241
-59
-20% -$26.1K ﹤0.01% 949
2025
Q3 		$137K Buy
300
+78
+35% +$31.8K ﹤0.01% 793
2025
Q2 		$72.4K Buy
222
+23
+12% +$6.36K ﹤0.01% 944
2025
Q1 		$53.7K Buy
199
+87
+78% +$22.4K ﹤0.01% 998
2024
Q4 		$26.4K Buy
112
+73
+187% +$19.2K ﹤0.01% 1115
2024
Q3 		$10.7K Buy
39
+12
+44% +$3.12K ﹤0.01% 1459
2024
Q2 		$6.56K Hold
27
– – ﹤0.01% 1379
2024
Q1 		$4.04K Buy
+27
New +$4.5K ﹤0.01% 1239

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Larson Financial Group's ALNY Position: Q3 2026 in Review

Larson Financial Group increased its Alnylam Pharmaceuticals (ALNY) stake by 204% in Q3 2026, buying an estimated $319K and bringing the position to 1,866 shares worth $460K. The position accounts for 0.01% of the portfolio, ranked #626.

Larson Financial Group first reported a position in ALNY in Q1 2024 and has held it in 11 quarters since. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Larson Financial Group held 1,866 shares of Alnylam Pharmaceuticals worth $460K as of Q3 2026.
  • Larson Financial Group bought 1,253 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $319K.
  • Alnylam Pharmaceuticals made up 0.01% of Larson Financial Group's portfolio in Q3 2026, its #626 holding.
  • Larson Financial Group first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.